MDLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medline Inc (MDLN) shows mixed signals for a beginner, long-term investor. While analyst ratings and price targets are positive, the company's recent financial performance shows declining net income, EPS, and gross margin. The technical indicators are neutral to slightly bullish, but there are no strong proprietary trading signals or significant catalysts to suggest an immediate buy. Given the user's impatience and preference for long-term investments, it is better to hold off on buying until stronger entry signals or improved financial performance emerge.
The MACD is positive at 0.142, suggesting slight bullish momentum, but it is contracting. RSI is neutral at 44.046, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 47.235, with support at 45.791 and resistance at 48.679.
Analysts have raised price targets significantly, with most maintaining Buy or Outperform ratings. The company's Q4 2025 revenue growth of 14.78% YoY and strong organic growth are positive indicators.
Net income dropped by 37.02% YoY, EPS declined by 41.67%, and gross margin fell by 9.56%. No recent news or significant trading trends from insiders or hedge funds. Congress trading data is also absent.
In Q4 2025, revenue increased to $7.787 billion, up 14.78% YoY. However, net income dropped to $182 million (-37.02% YoY), EPS fell to $0.21 (-41.67% YoY), and gross margin declined to 22.32% (-9.56% YoY).
Analysts are generally bullish, with multiple firms raising price targets to $53-$60 and maintaining Buy or Outperform ratings. The consensus highlights strong growth potential and margin expansion, though some concerns about conservative guidance remain.
